Background: Rosacea is a common disease, with an estimated prevalence of 5–10%. Established systemic and topical treatment is often effective but requires continuous medication. Aim: We report the outcome of photodynamic therapy (PDT) in 4 patients with rosacea. Methods: Prior treatment consisted of standard treatment with tetracycline and metronidazole. The treatment was however either ineffective or the patients were dissatisfied with the need for continuous treatment. The patients all received standard treatment with PDT. Results: The treated skin cleared in 3 of the 4 patients. Treatment with light alone did not appear to have any effect. In one of the patients there has been no relapse during a 9-month follow-up. In 2 patients, remissions lasted 3 months, during which time no additional or supplementary treatment was used. Conclusion: Our observation suggests that PDT may play a role in the future treatment of selected cases of rosacea.

Keywords:
Rosacea, Photodynamic therapy, 5-Aminolaevulinic acid, Methyl aminolaevulinate
1.
Plewig G, Kligman AM: Acne and Rosacea, ed 3. Berlin, Springer,2000, pp 456–501.
2.
Berg M, Liden S: An epidemiological study of rosacea. Acta Derm Venereol 1989;69:419–423.
3.
Gupta AK, Chaudhry MM: Evaluating the quality of rosacea studies: Implications for the patient and physician. Dermatology 2003;207:173–177.
4.
Dahl MV, Katz HI, Krueger GG, Millikan LE, Odom RB, Parker F, Wolf JE, Aly R, Bayles C, Reusser B, Weidner M, Coleman E, Patrignelli R, Tuley MR, Baker MO, Herndon JH, Czernielewski JM: Topical metronidazole maintains remissions of rosacea. Arch Dermatol 1999;135:79–80.
5.
Elewsik BE, Fleischer AB, Pariser DM: A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: Results of a randomised trial. Arch Dermatol 2003;139:1444–1450.
6.
Frampton JE, Wagstaff AJ: Azelaic acid 15% gel in the treatment of papulopustular rosacea. Am J Clin Dermatol 2004;5:57–64.
7.
Ibbotson SH: Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol 2002;146:178–188.
8.
Goldman MP, Boyce SM: A single-center study of aminolevulinic acid and 417 nm photodynamic therapy in the treatment of moderate to severe acne vulgaris. J Drugs Dermatol 2003;2:393–396.
9.
Hongcharu W, Taylor CR, Chang Y, Aghassi D, Suthamjariya K, Anderson RR: Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000;115:183–192.
10.
Gold M, Bridges TM, Bradshaw VL, Boring M: ALA-PDT and blue light therapy for hidradenitis suppurativa. J Drugs Dermatol 2004;3:32–35.
11.
Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ, Yamauchi PS: Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: Results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003;48:227–232.
12.
Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, Thai KE, Murrell D, Weightman W, Anderson C, Reid C, Watson A, Foley P: A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratoses: Prospective, randomized study. J Dermatol Treat 2003;14:99–106.
13.
Jeffes EW: Levulan: The first approved topical photosensitizer for the treatment of actinic keratosis. J Dermatol Treat 2002;13:19–23.
14.
Lang K, Schulte KW, Ruzicka T, Fritsch C: Aminolevulinic acid (Levulan) in photodynamic therapy of actinic keratosis. Skin Ther Lett 2001;6:1–2, 5.
15.
Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE: Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol 2001;62:140–145.
16.
Morton CA, Brown SB, Collins S, Ibbotson S, Jenkinson H, Kurwa H, Langmack K, Mckenna K, Moseley H, Pearse AD, Stringer M, Taylor DK, Wong G, Rhodes LE: Guidelines for topical photodynamic therapy: Report of a workshop of the British Photodermatology Group. Br J Dermatol 2002;146:552–567.
17.
Kligman AM: A personal critique on the state of knowledge of rosacea. Dermatology 2004;208:191–197.
18.
Aroni K, Tsagroni E, Lazaris AC, Patsouris E, Agapitos E: Rosacea: A clinicapathological approach. Dermatology 2004;209:177–182.
19.
Neubert U, Jansen T, Plewig G: Bacteriologic and immunologic aspects of gram-negative folliculitis: A study of 46 patients. Int J Dermatol 1999;38:270–274.
20.
Johansen Y, Wideroe HC, Krane J, Johnsson A: Proton magic angle spinning NMR reveals new features in photodynamically treated bacteria. Z Naturforsch 2003;58:401–407.
21.
Moon JS, Oh CH: Solar damage in skin tumors: Quantification of elastotic material. Dermatology 2001;202:289–292.
22.
Tisma VS, Basta-Juzbasic A, Dobric I, Ljubojevic S, Mokos ZB: Etiopathogenesis, classification, and current trends in treatment of rosacea. Acta Dermatovenereol Croat 2003;11:236–246.
23.
Engel A, Johnson ML, Haynes SG: Health effects of sunlight exposure in the United States: Results from the first National Health and Nutrition Examination Survey, 1971–1974. Arch Dermatol 1988;124:72–79.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.